Lorundrostat's Phase 2 Explore-CKD data is now in a top kidney journal, giving Mineralys Therapeutics (MLYS) a clearer clinical story focused on blood pressure and urinary protein reductions in chronic kidney disease patients.
Despite the Kidney International publication and a series of lorundrostat updates, Mineralys Therapeutics' share price return has been weak, with the stock down 52.39% year to date and 37.01% over 90 days. At the same time, a very large 3 year total shareholder return points to a much stronger earlier run that has since lost momentum.
Scan how Mineralys Therapeutics compares to other potential opportunities by reviewing a curated set of 31 resilient stocks with low risk scores that may offer a different balance between clinical pipelines and share price swings.
Mineralys Therapeutics now combines a sharp share price reset with cleaner lorundrostat data and a heavier loss profile. Does that mix still tilt the risk reward toward buyers at US$17 a share, or away from them?
Most Popular Narrative: 62% Undervalued
On the most followed view, Mineralys Therapeutics screens as deeply undervalued, with a fair value of about $45.22 against a last close of $17. That gap...